A Phase 1/2 Placebo-Controlled Randomized Observer-Blind Dose-Finding Study to Describe the Safety Tolerability Immunogenicity and Potential Efficacy of SARS CoV 2 RNA Vaccine Candidates Against COVID 19 in Healthy Adults

Go Back to All Clinical Trials

A Phase 1/2 Placebo-Controlled Randomized Observer-Blind Dose-Finding Study to Describe the Safety Tolerability Immunogenicity and Potential Efficacy of SARS CoV 2 RNA Vaccine Candidates Against COVID 19 in Healthy Adults

Brief description of study

The World Health Organization (WHO) has declared COVID-19 to be a pandemic; finding a vaccine to prevent COVID-19 is an urgent need. The study will compare the results of the people who receive the study vaccine with those who receive a placebo (a placebo does not contain any active ingredients). Participants will be assigned to one of the groups investigating one of the study vaccines, at one of the vaccine dose levels. All groups will have some people who get 2 placebo injections.

Clinical Study Identifier: s20-00515

ClinicalTrials.gov Identifier: NCT04368728

Clinical Research Studies

A Phase 1/2 Placebo-Controlled Randomized Observer-Blind Dose-Finding Study to Describe the Safety Tolerability Immunogenicity and Potential Efficacy of SARS CoV 2 RNA Vaccine Candidates Against COVID 19 in Healthy Adults

Brief description of study

Recruitment Status

212-263-4432

646-754-7432